b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">27587591</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>01</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>11</Month>\n            <Day>01</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1477-0334</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>27</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2018</Year>\n                        <Month>05</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Statistical methods in medical research</Title>\n                <ISOAbbreviation>Stat Methods Med Res</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Detecting and accounting for violations of the constancy assumption in non-inferiority clinical trials.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>1547-1558</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1177/0962280216665418</ELocationID>\n            <Abstract>\n                <AbstractText>Randomized, placebo-controlled clinical trials are the gold standard for evaluating a novel therapeutic agent. In some instances, it may not be considered ethical or desirable to complete a placebo-controlled clinical trial and, instead, the placebo is replaced by an active comparator with the objective of showing either superiority or non-inferiority to the active comparator. In a non-inferiority trial, the experimental treatment is considered non-inferior if it retains a pre-specified proportion of the effect of the active comparator as represented by the non-inferiority margin. A key assumption required for valid inference in the non-inferiority setting is the constancy assumption, which requires that the effect of the active comparator in the non-inferiority trial is consistent with the effect that was observed in previous trials. It has been shown that violations of the constancy assumption can result in a dramatic increase in the rate of incorrectly concluding non-inferiority in the presence of ineffective or even harmful treatment. In this paper, we illustrate how Bayesian hierarchical modeling can be used to facilitate multi-source smoothing of the data from the current trial with the data from historical studies, enabling direct probabilistic evaluation of the constancy assumption. We then show how this result can be used to adapt the non-inferiority margin when the constancy assumption is violated and present simulation results illustrating that our method controls the type-I error rate when the constancy assumption is violated, while retaining the power of the standard approach when the constancy assumption holds. We illustrate our adaptive procedure using a non-inferiority trial of raltegravir, an antiretroviral drug for the treatment of HIV.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Koopmeiners</LastName>\n                    <ForeName>Joseph S</ForeName>\n                    <Initials>JS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>1 Division of Biostatistics, School of Public Health, University of Minnesota, MN, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hobbs</LastName>\n                    <ForeName>Brian P</ForeName>\n                    <Initials>BP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>2 Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>P30 CA016672</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>R01 CA157458</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2016</Year>\n                <Month>09</Month>\n                <Day>01</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Stat Methods Med Res</MedlineTA>\n            <NlmUniqueID>9212457</NlmUniqueID>\n            <ISSNLinking>0962-2802</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName>\n                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000074099" MajorTopicYN="Y">Equivalence Trials as Topic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D013223" MajorTopicYN="Y">Statistics as Topic</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Bayesian hierarchical modeling</Keyword>\n            <Keyword MajorTopicYN="Y">HIV</Keyword>\n            <Keyword MajorTopicYN="Y">Non-inferiority trial</Keyword>\n            <Keyword MajorTopicYN="Y">constancy assumption</Keyword>\n            <Keyword MajorTopicYN="Y">multi-source smoothing</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2016</Year>\n                <Month>9</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>11</Month>\n                <Day>2</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2016</Year>\n                <Month>9</Month>\n                <Day>3</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">27587591</ArticleId>\n            <ArticleId IdType="pii">0962280216665418</ArticleId>\n            <ArticleId IdType="doi">10.1177/0962280216665418</ArticleId>\n            <ArticleId IdType="pmc">PMC5332430</ArticleId>\n            <ArticleId IdType="mid">NIHMS829868</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Stat Med. 2003 Jan 30;22(2):227-38</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12520559</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 2014 Mar;70(1):185-91</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24308779</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2011 Aug;8(4):432-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21835862</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2003 Jan 30;22(2):169-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12520555</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 2008 Jun;64(2):595-602</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17764481</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bayesian Anal. 2012 Sep;7(3):null</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24175005</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bayesian Anal. 2012 Aug 28;7(3):639-674</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24795786</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2008 May 15;358(20):2095-106</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18480202</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Chronic Dis. 1976 Mar;29(3):175-88</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">770493</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Biopharm Stat. 2015;25(1):206-25</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24918326</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2010 Feb;7(1):5-18</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20156954</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Infect Dis. 2013 Apr;13(4):303-12</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23433590</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2003 Jan 30;22(2):239-64</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12520560</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Biopharm Res. 2013 Jan 1;5(3):null</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24187607</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 1994 Jun;50(2):337-49</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7980801</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Biopharm Stat. 2008;18(1):81-115</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18161543</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2008 Feb 10;27(3):317-32</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17340597</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biometrics. 2011 Sep;67(3):1047-56</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21361892</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Trials. 2013;10(3):430-40</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23690095</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet. 2009 Sep 5;374(9692):796-806</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19647866</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Control Clin Trials. 2003 Apr;24(2):147-55</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12689736</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Lancet Infect Dis. 2011 Dec;11(12):907-15</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21933752</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Stat Med. 2010 Nov 30;29(27):2769-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20809482</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'